The independent source for health policy research, polling, and news.
161-180 of 478 results
The well-known âAmanita muscariaâ mushroom is legal to possess and consume in 49 states. The market for gummies, powders, and capsules containing extracts of the fungus is raising eyebrows, though, amid concerns from the FDA and in the absence of human clinical trials.
The 5th Circuit Court of Appeals in New Orleans heard oral arguments Wednesday in a case brought by conservative Christian abortion opponents seeking to revoke FDA approval of mifepristone, a medication used in more than half of abortions in the U.S.
The public health emergency declaration for covid-19 ends May 11, ushering in major changes in how Americans can access and pay for the vaccines, treatments, and tests particular to the culprit coronavirus. But not everyone will experience the same changes, creating a confusing patchwork of coverage â not unlike health coverage for other diseases. Meanwhile, outside advisers to the FDA formally recommended allowing a birth control pill to be sold without a prescription. If the FDA follows the recommendation, it would represent the first over-the-counter form of hormonal contraception. Margot Sanger-Katz of The New York Times, Tami Luhby of CNN, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join Ńîšóĺú´ŤĂ˝Ňîl Health Newsâ Julie Rovner to discuss these issues and more. Plus for âextra creditâ the panelists suggest health policy stories they read this week they think you should read, too.
As marijuana has become far more mainstream, potent, and sometimes dangerous, uneven regulation at the state and federal levels leaves consumers at risk.
New York and California have passed laws requiring disclosure of ingredients on menstrual product packaging. Advocates want more transparency across the U.S.
The Supreme Court on April 21 ruled that the abortion pill mifepristone should remain widely available while the lower courts consider the issue, blocking earlier rulings that banned or restricted access to the drug. Ńîšóĺú´ŤĂ˝Ňîl Health Newsâ Julie Rovner joined NPRâs âWeekend All Things Consideredâ to discuss the complicated case.
Online platforms are overflowing with testimonials for GLP-1s. The drugs show promise for inducing weight loss, but many arenât FDA-approved for that use.
The legality and availability of the abortion pill mifepristone is in question after a federal judge in Texas canceled the FDAâs approval of the first drug used in the two-drug medication abortion regimen. A 5th Circuit Court of Appeals panel overruled that decision in part, saying the pill should remain available, but only under the onerous restrictions in place before 2016. Meanwhile, another federal judge in Washington state issued a ruling in a separate case that conflicts with the Texas decision, ordering the FDA not to roll back any of its restrictions on the drug. Victoria Knight of Axios, Shefali Luthra of The 19th, and Sarah Karlin-Smith of the Pink Sheet join Ńîšóĺú´ŤĂ˝Ňîl Health News chief Washington correspondent Julie Rovner to discuss these issues and more.
The American Medical Association ducked the abortion issue for years and now sees its membersâ professional opinions second-guessed by lawmakers and judges. PhRMA is following the same playbook.
A KHN and CBS News investigation found that a dental appliance called the AGGA has been used by more than 10,000 patients, and multiple lawsuits allege it has caused grievous harm to patients.
A federal judge in Texas has dealt a big setback to the Affordable Care Act. The same judge who tried in 2018 to declare the entire ACA unconstitutional has now ruled that the lawâs main provisions for preventive care are unconstitutional and, therefore, unenforceable nationwide. Also this week, North Carolina became the 40th state to expand Medicaid under the ACA. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Sandhya Raman of CQ Roll Call join KHN chief Washington correspondent Julie Rovner to discuss these issues and more.
A U.S. District Court case is being widely followed because the judgeâs decision could overturn the FDAâs approval of mifepristone two decades ago. With abortion rights polling well even in red states, anti-abortion activists are increasingly turning to the courts to achieve their aims.
The FDAâs interest in the AGGA dental device follows a KHN-CBS News investigation, according to a former agency official.
The FDA has long blocked the importation of cheap medicine, agreeing with pharmaceutical manufacturers that it opens the door to opioids. The agencyâs own data shows that rarely happens.
President Joe Biden and Republicans in Congress spent last month sparring over whether to shield Medicare and Social Security from budget cuts â leading some to wonder if Medicaid was on the table instead. Biden and Democrats say no, but some Republicans seem eager to trim federal spending on the health program for Americans with low incomes. And ready or not, artificial intelligence is coming to medical care. Benefits, as well as unintended consequences, are likely. Alice Miranda Ollstein of Politico, Rachel Cohrs of STAT News, and Lauren Weber of The Washington Post join KHNâs chief Washington correspondent, Julie Rovner, to discuss these issues and more.
âWhat happens in Texas doesn't stay in Texas,â warns an abortion rights advocate bracing for a district judgeâs ruling on whether the abortion pill mifepristone was properly authorized by the FDA. His decision could force the medication off the U.S. market.
Patients who depend upon special drugs to treat rare diseases are caught in the crossfire as drugmakers and the FDA battle over regulations that reward companies for developing treatments for relatively small pools of patients.
President Joe Bidenâs 2023 State of the Union address leaned heavily on health care issues. Biden took a victory lap for recent accomplishments like capping prescription drug costs for seniors on Medicare. He also urged Congress to make permanent the boosted premium subsidies under the Affordable Care Act, and he sparred with Republicans on threats to cut Social Security and Medicare. Also this week, both sides in the abortion debate are bracing for a court decision out of Texas that could, at least temporarily, make the abortion pill mifepristone illegal nationwide. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Sarah Karlin-Smith of the Pink Sheet join KHN chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Kate Baicker of the University of Chicago about a possible middle ground in the effort to get universal health insurance coverage.
As he takes the reins of the Senate Health, Education, Labor & Pensions Committee, the independent from Vermont and implacable champion of âMedicare for Allâ maps out his strategy for negotiating with Republicans â and Big Pharma.
A single booster seems to prevent death and hospitalization in most people, but protection from the current vaccines wanes within months. FDA experts say they need to know more from the Centers for Disease Control and Prevention to decide the best long-term strategy.
Š 2026 KFF